Evaluating Glucose Control Using a Next-Generation AID Algorithm in Adults With T1D

Inclusion Criteria: * Age at time of consent 16-70 years (inclusive) * Type 1 diabetes diagnosis for at least 6 months, based on Investigator assessment * Basal/Bolus insulin delivery via multiple daily injections or insulin pump with or without automation * Willing to use the following types of U-100 insulin during the study: Humalog U-100, Novorapid or their generic equivalents * Deemed appropriate for pump therapy per Investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities * If using noninsulin glucose-lowering medications or weight reduction medications, dose has been stable for 6-weeks prior to screening; and participant is willing to not change the dose unless required for safety purposes. * Investigator has confidence that the participant can safely operate all study devices and can adhere to the protocol * Willing to wear the system continuously throughout the study * Willing and able to sign the Informed Consent Form (ICF) * Able to read and understand English * If of childbearing potential, willing and able to have pregnancy testing Exclusion Criteria: * Any medical condition, which in the opinion of the Investigator, would put the participant at an unacceptable safety risk. This may include untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, unstable proliferative retinopathy, unstable psychiatric conditions such as eating disorders, drug or alcohol abuse. * …